The DOI matches its Crossref record; 44 of the 45 references it cites were found in a registry or an index.
ANGPTL3 Deficiency and Protection Against Coronary Artery Disease
Open accessAbstract
BACKGROUND: Familial combined hypolipidemia, a Mendelian condition characterized by substantial reductions in all 3 major lipid fractions, is caused by mutations that inactivate the gene angiopoietin-like 3 (ANGPTL3). Whether ANGPTL3 deficiency reduces risk of coronary artery disease (CAD) is unknown. OBJECTIVES: The study goal was to leverage 3 distinct lines of evidence-a family that included individuals with complete (compound heterozygote) ANGPTL3 deficiency, a population based-study of humans with partial (heterozygote) ANGPTL3 deficiency, and biomarker levels in patients with myocardial infarction (MI)-to test whether ANGPTL3 deficiency is associated with lower risk for CAD. METHODS: We assessed coronary atherosclerotic burden in 3 individuals with complete ANGPTL3 deficiency and 3 wild-type first-degree relatives using computed tomography angiography. In the population, ANGPTL3 loss-of-function (LOF) mutations were ascertained in up to 21,980 people with CAD and 158,200 control subjects. LOF mutations were defined as nonsense, frameshift, and splice-site variants, along with missense variants resulting in <25% of wild-type ANGPTL3 activity in a mouse model. In a biomarker study, circulating ANGPTL3 concentration was measured in 1,493 people who presented with MI and 3,232 control subjects. RESULTS: The 3 individuals with complete ANGPTL3 deficiency showed no evidence of coronary atherosclerotic plaque. ANGPTL3 gene sequencing demonstrated that approximately 1 in 309 people was a heterozygous carrier for an LOF mutation. Compared with those without mutation, heterozygous carriers of ANGPTL3 LOF mutations demonstrated a 17% reduction in circulating triglycerides and a 12% reduction in low-density lipoprotein cholesterol. Carrier status was associated with a 34% reduction in odds of CAD (odds ratio: 0.66; 95% confidence interval: 0.44 to 0.98; p = 0.04). Individuals in the lowest tertile of circulating ANGPTL3 concentrations, compared with the highest, had reduced odds of MI (adjusted odds ratio: 0.65; 95% confidence interval: 0.55 to 0.77; p < 0.001). CONCLUSIONS: ANGPTL3 deficiency is associated with protection from CAD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Similarly, with genetic studies supporting the role of several novel therapeutic targets (eg, apo C-III and ANGPTL3) in atherosclerosis, ongoing clinical trials using RNA interference therapy (antisense oligonucleotides and small interfering RNAs) have the potential to further inform our understanding of the triglyceride-based atherosclerotic pathways (120,121).”
From 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia (2021) · cites this paper as [121]
The cited source says what the claim attributes to it.
In the citing paper
“Carriers of loss-of-function (LOF) variants in ANGTPL3 present with low triglyceride, low LDL (low-density lipoprotein) cholesterol (LDL-C), and low HDL (high-density lipoprotein) cholesterol (HDL-C) plasma levels,1 as well as a decreased risk for cardiovascular disease compared with non-carriers.2,3”
In the citing paper
“Mendelian randomization studies focused on variants in the genes encoding apoAV, apoCIII, lipoprotein lipase (LpL) and the angiopoietin-like proteins 3, 4, and 8 (ANGPTL3, ANGPTL4, and ANGPTL8) have been highly informative.29–35”
In the citing paper
“Loss-of-function variants in ANGPTL3 have been associated with reduced plasma levels of TG, LDL-C, and HDL-C.32,64,65”
In the citing paper
“individuals with ANGPTL3 LOF variants have low levels of TG, LDL-C, and HDL-C.32,65”
In the citing paper
“These hypotriglyceridaemic states contrast with mild HTG and increased ASCVD risk seen with heterozygous LOF mutations in APOA5.11”
From Clinical review on triglycerides (2020) · cites this paper as [11]
In the citing paper
“Similarly, heterozygous LOF variants in ANGPTL311 and ANGPTL412 genes are associated with reductions both in plasma TG and ASCVD risk.”
From Clinical review on triglycerides (2020) · cites this paper as [11]
In the citing paper
“ANGPTL3 is a genetically validated target for HTG to reduce ASCVD risk.11,77–79”
From Clinical review on triglycerides (2020) · cites this paper as [11]
In the citing paper
“Recently, the EpanoVa fOr Lowering Very high triglyceridEs II (EVOLVE II) trial confirmed the efficacy of omega-3 fatty acids in lowering serum TGs [327].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [327]
In the citing paper
“Genetic loss-of-function variants in ANGPTL3 are associated with lower levels of plasma lipids.”
From Effect of Vupanorsen on Non–High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70 (2022) · cites this paper as [12]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P., Danesh, J., Downey, P., Elliott, P., Green, J., Landray, M., et al. (2015) · PLOS Medicine · doi:10.1371/journal.pmed.1001779 · Cited by 12,728
Self-citationSequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Self-citationGenomewide Association Analysis of Coronary Artery Disease
Samani, N. J., Erdmann, J., Hall, A. S., Hengstenberg, C., Mangino, M., Mayer, B., Dixon, R. J., Meitinger, T., Braund, P., Wichmann, H.-E., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072366 · Cited by 2,044
Self-citationGenetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease
Clarke, R., Peden, J. F., Hopewell, J. C., Kyriakou, T., Goel, A., Heath, S. C., Parish, S., Barlera, S., Franzosi, M. G., Rust, S., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902604 · Cited by 1,671
A Common Allele on Chromosome 9 Associated with Coronary Heart Disease
McPherson, R., Pertsemlidis, A., Kavaslar, N., Stewart, A., Roberts, R., Cox, D. R., Hinds, D. A., Pennacchio, L. A., Tybjaerg-Hansen, A., Folsom, A. R., et al. (2007) · Science · doi:10.1126/science.1142447 · Cited by 1,587
Self-citationLoss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease
The TG and HDL Working Group of the Exome Sequencing Project, N. H. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1307095 · Cited by 1,071
Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
Jørgensen, A. B., Frikke-Schmidt, R., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308027 · Cited by 919
Exome Sequencing, ANGPTL3 Mutations, and Familial Combined Hypolipidemia
Musunuru, K., Pirruccello, J. P., Do, R., Peloso, G. M., Guiducci, C., Sougnez, C., Garimella, K. V., Fisher, S., Abreu, J., Barry, A. J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002926 · Cited by 754
Self-citationTobin, M. D., Sheehan, N. A., Scurrah, K. J., & Burton, P. R. (2005) · Statistics in Medicine · doi:10.1002/sim.2165 · Cited by 695
Flagged first, then by citations
1 of the 45 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 201–300 of 470
Burks, K. H., Xie, Y., Gildea, M. A., Jung, I., Mukherjee, S. K., Lee, P. C., Pudupakkam, U., Wagoner, R., Patel, V., Santana, K., et al. (2024) · Journal of Lipid Research · doi:10.1016/j.jlr.2024.100500 · Cited by 19
Self-citationNew approaches to address dyslipidemia
Parhofer, K. G. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000456 · Cited by 19
Liu, J., Yagi, K., Nohara, A., Chujo, D., Ohbatake, A., Fujimoto, A., Miyamoto, Y., Kobayashi, J., & Yamagishi, M. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.12.011 · Cited by 19
Surma, S., Romańczyk, M., & Filipiak, K. J. (2021) · Cardiology Journal · doi:10.5603/cj.a2021.0006 · Cited by 19
Novel Experimental Agents for the Treatment of Hypercholesterolemia
Pećin, I., & Reiner, Ž. (2021) · Journal of Experimental Pharmacology · doi:10.2147/jep.s267376 · Cited by 19
Bell, T. A., Liu, M., Donner, A. J., Lee, R. G., Mullick, A. E., & Crooke, R. M. (2021) · Journal of Lipid Research · doi:10.1016/j.jlr.2021.100101 · Cited by 19
Wang, J., Zheng, W., Zheng, S., Yuan, Y., Wen, W., Cui, W., Xue, L., Sun, X., Shang, H., Zhang, H., et al. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.11.023 · Cited by 18
Colesterol remanente, riesgo vascular y prevención de la arteriosclerosis
Pintó, X., Fanlo‐Maresma, M., Esteve, V., Millán, J., Blanco, A., Blasco, M., Díaz-Díaz, J. L., Rodríguez, Á. D., Mangas, A., Pascual, V., et al. (2023) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2023.02.001 · Cited by 18
Khan, S. U., Saeed, S., Alsuhaibani, A. M., Fatima, S., Rehman, K. U., Zaman, U., Ullah, M., Refat, M. S. E.-D., & Lu, K. (2023) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2023.101821 · Cited by 19
New Biological Therapies for Low-Density Lipoprotein Cholesterol
Gill, P. K., & Hegele, R. A. (2023) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2023.08.003 · Cited by 18
Development of New Genome Editing Tools for the Treatment of Hyperlipidemia
Preta, G. (2023) · Cells · doi:10.3390/cells12202466 · Cited by 19
Tarugi, P., Bertolini, S., Calandra, S., Arca, M., Angelico, F., Casula, M., Cefalu, A. B., D’Erasmo, L., Fortunato, G., Filardi, P. P., et al. (2024) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2024.05.002 · Cited by 18
Macromolecular Interactions of Lipoprotein Lipase (LPL)
Wheless, A., Gunn, K. H., & Neher, S. B. (2024) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-3-031-58843-3_8 · Cited by 19
Chan, D. C., & Watts, G. F. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01254-y · Cited by 19
Chen, M., Hsu, B., Lee, C., & Wang, J. (2020) · International Journal of Hypertension · doi:10.1155/2020/2980954 · Cited by 18
Ruhanen, H., Haridas, P. A. N., Jauhiainen, M., & Olkkonen, V. M. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2020.158791 · Cited by 18
Transcriptomic Therapy for Dyslipidemias Utilizing Nucleic Acids Targeted at ANGPTL3
Watts, G. F., Raal, F. J., & Chan, D. C. (2021) · Future Cardiology · doi:10.2217/fca-2021-0096 · Cited by 18
A Tale of Two New Targets for Hypertriglyceridaemia: Which Choice of Therapy?
Ward, N. C., Chan, D. C., & Watts, G. F. (2022) · BioDrugs · doi:10.1007/s40259-022-00520-2 · Cited by 18
A CRISPR edit for heart disease
King, A. (2018) · Nature · doi:10.1038/d41586-018-02482-4 · Cited by 18
Hussain, A., & Ballantyne, C. M. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-100119-013612 · Cited by 19
Park, C. Y., Moon, J., Jo, G., Lee, J., Kim, O. Y., Oh, H., Lim, H., & Shin, M. (2019) · Scientific Reports · doi:10.1038/s41598-018-36581-z · Cited by 17
Management of dyslipidemia in coronary artery disease: the present and the future
Dimitriadis, K. S., Theofilis, P., Iliakis, P., Pyrpyris, N., Dri, E., Sakalidis, A., Σουλαϊδόπουλος, Σ., Tsioufis, P., Fragkoulis, C., Chrysohoou, C. A., et al. (2024) · Coronary Artery Disease · doi:10.1097/mca.0000000000001375 · Cited by 17
Rare damaging CCR2 variants are associated with lower lifetime cardiovascular risk
Georgakis, M. K., Malik, R., Bounkari, O. E., Hasbani, N. R., Li, J., Huffman, J. E., Shakt, G. E., Tack, R. W. P., Kimball, T. N., Asare, Y., et al. (2025) · Genome Medicine · doi:10.1186/s13073-025-01456-2 · Cited by 16
Associations Between Plasma Betatrophin Levels and Coronary and Peripheral Artery Disease
Niki, H., Kishimoto, Y., Ibe, S., Saita, E., Sasaki, K., Miura, K., Ikegami, Y., Ohmori, R., Kondo, K. N., & Momiyama, Y. (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.46508 · Cited by 16
LDL-Cholesterol-Lowering Therapy
Pirillo, A., Norata, G. D., & Catapano, A. L. (2020) · Handbook of experimental pharmacology · doi:10.1007/164_2020_361 · Cited by 17
Vekić, J., Zeljković, A., Stefanović, A., Bogavac‐Stanojević, N., Ilias, Ι., Silva‐Nunes, J., Stoian, A. P., Janež, A., & Rizzo, M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14040825 · Cited by 16
Ruhanen, H., Haridas, P. A. N., Minicocci, I., Taskinen, J., Palmas, F., Costanzo, A. D., D’Erasmo, L., Metso, J., Partanen, J., Dalli, J., et al. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2020.158679 · Cited by 16
Homozygous familial hypercholesterolemia: what treatments are on the horizon?
Bajaj, A., & Cuchel, M. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000677 · Cited by 17
Reeskamp, L. F., Tromp, T. R., Huijgen, R., Stroes, E. S. G., Hovingh, G. K., & Grefhorst, A. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.11.013 · Cited by 17
Jordan, D. M., Verbanck, M., & Do, R. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/311332 · Cited by 16
How ANGPTL3 Inhibition Will Help Our Clinical Practice?
Bini, S., Tramontano, D., Minicocci, I., Costanzo, A. D., Tambaro, F., D’Erasmo, L., & Arca, M. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01076-w · Cited by 15
Xu, X., Xu, H., Liu, X., Zhang, S., Cao, Z., Qiu, L., Du, X., Liu, Y., Wang, G., Zhang, L., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1199429 · Cited by 15
Targeting angiopoietin‐like 3 in atherosclerosis: From bench to bedside
Ling, P., Zheng, X., Luo, S., Ge, J., Xu, S., & Weng, J. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14450 · Cited by 15
Evinacumab for treatment of familial hypercholesterolemia
Warden, B. A., & Duell, P. B. (2021) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2021.1955349 · Cited by 16
Familial Hypercholesterolemia: Challenges for a High-Risk Population
Choi, D., Malick, W. A., Köenig, W., Rader, D. J., & Rosenson, R. S. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.02.038 · Cited by 15
Self-citationHow to Handle Elevated Triglycerides: Life after PROMINENT
Pirillo, A., & Catapano, A. L. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01175-2 · Cited by 15
Large-Scale Genomic Biobanks and Cardiovascular Disease
Small, A., O’Donnell, C. J., & Damrauer, S. M. (2018) · Current Cardiology Reports · doi:10.1007/s11886-018-0969-8 · Cited by 16
Whyte, M. P., McAlister, W. H., Mumm, S. R., & Bierhals, A. J. (2019) · Bone · doi:10.1016/j.bone.2019.02.025 · Cited by 15
Self-citationMurawska, K., Krintus, M., Kuligowska-Prusińska, M., Szternel, Ł., Stefańska, A., & Sypniewska, G. (2021) · Nutrients · doi:10.3390/nu13124339 · Cited by 14
Familial hypercholesterolemia – treatment update in children, systematic review
Ziółkowska, S., Kijek, N., Zendran, I., Szuster, E., & Barg, E. (2022) · Pediatric Endocrinology Diabetes and Metabolism · doi:10.5114/pedm.2022.116112 · Cited by 15
Jianu, N., Nițu, E.-T., Merlan, C., Nour, A., Buda, S., Suciu, M., Luca, S. A., Sbârcea, L., Andor, M., & Buda, V. O. (2025) · Pharmaceuticals · doi:10.3390/ph18081150 · Cited by 14
Li, J., Yang, Y., Jiao, X., Yu, H., Du, Y., Zhang, M., Hu, C., Wei, Y., & Qin, Y. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-06991-1 · Cited by 15
ANGPTL3 gene variants in subjects with familial combined hyperlipidemia
Bea, A. M., Franco-Marín, E., Marco-Benedí, V., Jarauta, E., Gracia‐Rubio, I., Cenarro, A., Civeira, F., & Lamíquiz-Moneo, I. (2021) · Scientific Reports · doi:10.1038/s41598-021-86384-y · Cited by 14
Evinacumab: a new option in the treatment of homozygous familial hypercholesterolemia
Pirillo, A., & Catapano, A. L. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2090242 · Cited by 14
Lin, C.-Y., Chen, P., Hsu, H., Gao, W.-Y., Wu, M., & Yen, J.-H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012485 · Cited by 14
Musunuru, K., Arora, P. K., Cooke, J. P., Ferguson, J. F., Hershberger, R. E., Hickey, K. T., Lee, J., Lima, J. A. C., Loscalzo, J., Pereira, N. L., et al. (2018) · Circulation Genomic and Precision Medicine · doi:10.1161/hcg.0000000000000046 · Cited by 14
Self-citationFlorentin, M., Kostapanos, M. S., Anagnostis, P. G., & Liamis, G. L. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1691523 · Cited by 14
Melita, H., Manolis, A. A., Manolis, T. A., & Manolis, A. S. (2022) · PubMed · doi:10.1097/fjc.0000000000001160 · Cited by 13
Ren, Z., Zhou, J., Yang, D., Guo, Y., Zhang, J., Xu, J., & Chen, Y. E. (2026) · Cells · doi:10.3390/cells15020134 · Cited by 13
Mechanisms of unusual response to lipid-lowering therapy: PCSK9 inhibition
Ouyang, M., Li, C., Hu, D., Peng, D., & Yu, B. (2022) · Clinica Chimica Acta · doi:10.1016/j.cca.2022.11.018 · Cited by 13
Self-citationA significant presence in atherosclerotic cardiovascular disease: Remnant cholesterol: A review
Wang, L., Zhang, Q., Wu, Z., & Huang, X. (2024) · Medicine · doi:10.1097/md.0000000000038754 · Cited by 13
The Role of Non-statin Lipid-Lowering Medications in Youth with Hypercholesterolemia
Butt, W. Z., & Yee, J. K. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01013-x · Cited by 13
Mszar, R., Bart, S., Sakers, A. P., Soffer, D. E., & Karalis, D. G. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12041382 · Cited by 14
Zhang, Y., Zhang, Z.-T., Wan, S.-Y., Yang, J. X., Wei, Y., Chen, H., Zhou, W.-Z., Song, Q., Niu, S., Zheng, L., et al. (2023) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjad053 · Cited by 13
Treating Dyslipidemia in Type 2 Diabetes
Nelson, A. J., & Nicholls, S. J. (2018) · Cardiology Clinics · doi:10.1016/j.ccl.2017.12.005 · Cited by 13
Comparison of angiopoietin-like protein 3 and 4 reveals structural and mechanistic similarities
Gunn, K. H., Gutgsell, A. R., Xu, Y., Johnson, C. V., Liu, J., & Neher, S. B. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100312 · Cited by 12
Sadeghabadi, Z. A., Nourbakhsh, M., Alaee, M. R., Nourbakhsh, M., Ghorbanhosseini, S. S., Sharifi, R., & Razzaghy‐Azar, M. (2021) · International Journal of Hypertension · doi:10.1155/2021/6748515 · Cited by 12
Therapeutic application of genome editing in dyslipidemia
Whittaker, M. N., & Musunuru, K. (2021) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000805 · Cited by 12
Self-citationVariants in the GPR146 Gene Are Associated With a Favorable Cardiometabolic Risk Profile
Rimbert, A., Yeung, M. W., Dalila, N., Thio, C. H. L., Yu, H., Loaiza, N., Oldoni, F., van der Graaf, A., Wang, S., Said, M. A., et al. (2022) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.122.317514 · Cited by 12
Remnant cholesterol, vascular risk, and prevention of atherosclerosis
Pintó, X., Fanlo‐Maresma, M., Esteve-Luque, V., & Millán, J. (2023) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2023.07.005 · Cited by 13
Povsic, T. J., Scott, R. C., Mahaffey, K. W., Blaustein, R. O., Edelberg, J. M., Lefkowitz, M. P., Solomon, S. D., Fox, J. C., Healy, K. E., Khakoo, A. Y., et al. (2017) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-017-6739-9 · Cited by 12
The Future of Lipid-Lowering Therapy
Zwol, W. H.-V., Rimbert, A., & Kuivenhoven, J. A. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8071085 · Cited by 12
Recent Advances in the Management of Dyslipidemia: A Systematic Review
Feng, H. J. X., Yousaf, A., Moon, J., Ramiz, A., Krishma, U., & Pemminati, S. (2025) · Cureus · doi:10.7759/cureus.81034 · Cited by 15
Zhao, Y., Goto, M., Vaziri, N. D., Khazaeli, M., Liu, H., Farahanchi, N., Khanifar, E., Farzaneh, T., Haslett, P. A. J., Moradi, H., et al. (2020) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.120.000257 · Cited by 11
ANGPLT3 in cardio-metabolic disorders
Su, X. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06248-6 · Cited by 11
Yang, S., Jiao, X., Huo, X., Zhu, M., Wang, Y., Fang, X., Yang, Y., Yue, W., & Qin, Y. (2018) · Lipids in Health and Disease · doi:10.1186/s12944-018-0802-9 · Cited by 11
Transcriptional changes during isoproterenol-induced cardiac fibrosis in mice
Nanda, D., Pant, P., Machha, P., Sowpati, D. T., & Kumarswamy, R. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1263913 · Cited by 10
Jamadade, P., Nupur, N., Maharana, K. C., & Singh, S. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01228-0 · Cited by 11
Syndromic Retinitis Pigmentosa: A Narrative Review
Janáky, M., & Braunitzer, G. (2025) · Vision · doi:10.3390/vision9010007 · Cited by 10
Wen, Y., Lemen, D., Lin, Y., Chen, Y., Regmi, A., Roell, W. C., Thomas, M. K., Hartman, M. L., Coşkun, T., Miličević, Z., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16661 · Cited by 11
RNA interference-based therapies for the control of atherosclerosis risk factors
Kettunen, S., Ruotsalainen, A., & Ylä‐Herttuala, S. (2022) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000972 · Cited by 10
A New Modality in Dyslipidemia Treatment: Antisense Oligonucleotide Therapy
Kim, K., & Choi, S. H. (2022) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2022.11.3.250 · Cited by 11
Mak, M. C. E., Gurung, R., & Foo, R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814057 · Cited by 10
Biotechnology Approaches for the Treatment of Dyslipidemia
Parolini, C. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07017-6 · Cited by 10
Khera, A. V., Wang, M., Chaffin, M. D., Emdin, C. A., Samani, N. J., Schunkert, H., Watkins, H. C., McPherson, R., Erdmann, J., Elosúa, R., et al. (2022) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.121.003598 · Cited by 10
Self-citationFu, Y.-S., Wang, J., Lee, C., & Hsu, B. (2018) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s150476 · Cited by 10
How Genome Editing could be used in the Treatment of Cardiovascular Diseases
Musunuru, K. (2018) · Personalized Medicine · doi:10.2217/pme-2017-0078 · Cited by 10
Self-citationEffect of complete, lifelong ANGPTL3 deficiency on triglyceride-rich lipoprotein kinetics
Fappi, A., Patterson, B. W., Burks, K. H., Davidson, N. O., Vaisar, T., Kanter, J. E., Bornfeldt, K., Fisher, E. A., Goldberg, I. J., Stitziel, N. O., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102152 · Cited by 9
Self-citationGene Editing Therapy in Cardiovascular Disease: 2026 ACC Scientific Statement
Ambardekar, A. V., Bhatt, A., Hoekstra, M., Kelly, M., Musunuru, K., & Natarajan, P. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.02.5092 · Cited by 10
Self-citationLipid management to mitigate poorer postkidney transplant outcomes
Skulratanasak, P., & Larpparisuth, N. (2022) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000841 · Cited by 10
Tokgözoğlu, L. S., Pirillo, A., & Catapano, A. L. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad485 · Cited by 9
Zhao, D., Gao, X., Zhou, J., Li, J., Qian, Y., Wang, D., Niu, W., Zhang, T., Hu, M., Xiong, H., et al. (2023) · BMC Biology · doi:10.1186/s12915-023-01754-4 · Cited by 9
Watts, G. F., & Chan, D. C. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1484 · Cited by 9
Genetics of remnant cholesterol
Wulff, A. B., & Nordestgaard, B. G. (2025) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000991 · Cited by 8
Lv, Q., Jiao, X., Yu, H., Sun, Q., Fan, L., Wang, Y., Sun, H., Du, Z., Li, L., Hu, C., et al. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.122.025955 · Cited by 8
Gumanova, N. G., Bogdanova, N. L., Metelskaya, V. A., Tarasov, V. I., Kots, A. Y., Kutsenko, V. A., Васильевна, К. А., & Drapkina, O. M. (2022) · Scientific Reports · doi:10.1038/s41598-022-22367-x · Cited by 9
Srivastava, R. A. K. (2023) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2023.08.010 · Cited by 8
Lin, W., Zhang, S., Gu, C., Zhu, H., & Liu, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1280525 · Cited by 8
Evinacumab for Homozygous Familial Hypercholesterolemia: The Italian Cohort of the ELIPSE HoFH Study
Iannuzzo, G., Calcaterra, I. L., Gentile, M., Stanzione, C., Ruberto, F. D., Taranto, M. D. D., Fortunato, G., & Minno, M. N. D. D. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03160-4 · Cited by 9
Han, X., Dai, R., Zhai, Y., Shen, Q., Sun, L., Liu, H., & Xu, H. M. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.06.065 · Cited by 8
Approach to patients with hypertriglyceridemia
Chait, A., & Feingold, K. R. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101659 · Cited by 8
Non-coding RNA-Associated Therapeutic Strategies in Atherosclerosis
Tang, Y., Li, H., & Chen, C. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.889743 · Cited by 8
Do we need new lipid-lowering agents in the era of PCSK9 inhibitors? Recent advances
Atar, D., Langslet, G., & Tonstad, S. (2022) · Kardiologia Polska · doi:10.33963/kp.a2022.0117 · Cited by 8
Targeting triglycerides to lower residual cardiovascular risk
Bubb, K. J., Nelson, A. J., & Nicholls, S. J. (2022) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2022.2058489 · Cited by 8
Genome Editing in Dyslipidemia and Atherosclerosis
Chen, Z., Lehertshuber, C., & Schunkert, H. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-981-19-5642-3_10 · Cited by 8
Self-citationGene Therapy Approaches for Atherosclerosis Focusing on Targeting Lipid Metabolism and Inflammation
Bezsonov, E. E., Chernyi, N., Saruhanyan, M., Shimchenko, D., Bondar, N., Gavrilova, D., Baig, M. S., & Malogolovkin, A. S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146950 · Cited by 8
Bohn, B., Lutsey, P. L., Tang, W., Pankow, J. S., Norby, F. L., Yu, B., Ballantyne, C. M., Whitsel, E. A., Matsushita, K., & Demmer, R. T. (2022) · Journal of Proteomics · doi:10.1016/j.jprot.2022.104788 · Cited by 9
Self-citationYoung, E. P., & Stitziel, N. O. (2018) · Annual Review of Medicine · doi:10.1146/annurev-med-041717-085853 · Cited by 7
Self-citationAngiopoietin-like Proteins in Colorectal Cancer—A Literature Review
Zajkowska, M., & Mroczko, B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168439 · Cited by 7
Hsiao, C.-H., Chen, Y., Wang, J., & Hsu, B. (2021) · Medicina · doi:10.3390/medicina57101011 · Cited by 7
Metadata
- Authors
- Stitziel, N. O., Khera, A. V., Wang, X., Bierhals, A. J., Vourakis, A. C., Sperry, A. E., Natarajan, P., Klarin, D., Emdin, C. A., Zekavat, S. M., Nomura, A., Erdmann, J., Schunkert, H., Samani, N. J., Kraus, W. E., Shah, S. H., Yu, B., Boerwinkle, E., Rader, D. J., Gupta, N., Frossard, P. M., Rasheed, A., Danesh, J., Lander, E. S., Gabriel, S., Saleheen, D., Musunuru, K., & Kathiresan, S.
- Affiliations
- Washington University in St. Louis (US)
- Broad Institute (US)
- Harvard University (US)
- Institute for Integrative and Experimental Genomics (DE)
- German Centre for Cardiovascular Research (DE)
- University of Leicester (GB)
- Duke University (US)
- Baylor College of Medicine (US)
- University of Pennsylvania (US)
- Center for Non-Communicable Diseases (PK)
- University of Cambridge (GB)
- Corresponding author
- Stitziel, Nathan O.
- ORCID
- Stitziel, Nathan O.
- Khera, Amit V.
- Bierhals, Andrew J.
- Sperry, Alexandra E.
- Natarajan, Pradeep
- Klarin, Derek
- Emdin, Connor A.
- Zekavat, Seyedeh M.
- Nomura, Akihiro
- Erdmann, Jeanette
- Schunkert, Heribert
- Samani, Nilesh J.
- Kraus, William E.
- Shah, Svati H.
- Yu, Bing
- Boerwinkle, Eric
- Rader, Daniel J.
- Gupta, Namrata
- Danesh, John
- Lander, Eric S.
- Gabriel, Stacey
- Saleheen, Danish
- Musunuru, Kiran
- Kathiresan, Sekar
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2017-04
- Volume
- 69
- Issue
- 16
- Pages
- 2054-2063
- ISSN
- 0735-1097 (ISSN-L)
- PMC
- PMC5404817
- OpenAlex
- W2604768034
- Cited by
- 467
- References
- 45
- Citations by year
- 2026: 38 · 2025: 39 · 2024: 46 · 2023: 58 · 2022: 57 · 2021: 70 · 2020: 44 · 2019: 36 · 2018: 54 · 2017: 23
- FWCI
- 33.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of the American College of Cardiology (publishedVersion, other-oa)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Apollo (University of Cambridge) (submittedVersion, cc-by-nc-nd)
- Apollo
- Funders
- Harvard Catalyst
- National Institute for Health and Care Research (NF-SI-0512-10165)
- British Heart Foundation (RG/08/014/24067)
- National Institutes of Health (5t32hl007734-30, KL2TR001100)
- Medical Research Council (MR/L003120/1)
- National Heart, Lung, and Blood Institute (R01HL127564, K08HL114642, R33HL120781, R21HL120781, T-32HL007734, RC2HL101834, R01HL118744, R01HL131961)
- National Human Genome Research Institute (UM1HG008895, U54HG003067, UM1HG008853)
- Fogarty International Center (RC1TW008485)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
- Keywords
- ANGPTL3, coronary artery disease, loss-of-function mutations, myocardial infarction, triglycerides, LDL cholesterol, genetic risk, heterozygous carriers, hypolipidemic effect, first-degree relatives, loss-of-function screening
- MeSH terms
- Angiopoietin-like Proteins, Angiopoietin-Like Protein 3, Adult, Animals, Coronary Artery Disease, Female, Humans, Lipids, Male, Mice, Inbred C57BL, Middle Aged, Myocardial Infarction, Risk Factors, Case-Control Studies, Mice, Knockout, Mutation, Missense, Angiopoietins, Atherosclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
